LMR Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

LMR Partners’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-974	Closed	-$53K	–	1029
2021 Q2	$53K	Buy	+974	New	+$54.1K	﹤0.01%	982

Other funds holding CRBP

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LMR Partners's CRBP Position: Q3 2021 in Review

LMR Partners sold out of Corbus Pharmaceuticals (CRBP) in Q3 2021, closing a stake of 974 shares — an estimated $53K sold.

LMR Partners first reported a position in CRBP in Q2 2021 and held it in 1 quarter. The position peaked at $53K in Q2 2021. 85 funds tracked by Wall St. Rank hold CRBP as of Q3 2021.

LMR Partners reported no remaining Corbus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
LMR Partners sold 974 Corbus Pharmaceuticals shares in Q3 2021, an estimated $53K.
LMR Partners first reported a position in Corbus Pharmaceuticals in Q2 2021 and held it in 1 quarter.
LMR Partners's Corbus Pharmaceuticals position peaked at $53K in Q2 2021.
85 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.